undamentalytics Newsletter
Sign in

Dariohealth Corp. (DRIO) stock

Add to watchlist

Add holding +

NASDAQ: DRIO Nasdaq Health Care Technology Next results ~November 12, 2026

E Fundamentals grade

Dariohealth Corp. is a US-listed company in the health care technology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$1.1

Price-to-sales vs peers

Base case. Range ~$1.1–$12. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Dariohealth Corp. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling1 purchase and 0 sales by directors and officers, last 12 monthsInsider trades

Value diary

Our note on each quarter Dariohealth files

Where Dariohealth stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $21m, down 22.6% on a year earlier, a smaller fall than the 24.4% decline a quarter earlier. That puts it 19 of 19 for growth among the health care technology companies we cover. Free-cash-flow margin fell to -121.3% from -99.2% a year earlier. Operating margin widened to -151.6% from -155.8%. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 1 of our 6 financial-health checks. Our price-to-sales vs peers value is $1.40 a share, against a share price of $3.33.

Source: 10-Q filed August 11, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Dariohealth Corp.'s trailing-twelve-month revenue fell 22.6% year on year, with a free-cash-flow margin of -121.3%. Where it lags: revenue growth of -22.6% ranks 23 of 23 health care technology companies we cover.

Current signal Gross margin expanding: TTM gross margin reached 58.2%, up 3.2pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 4.2 points on a year ago.

Things to watch

  • Revenue shrinking. Revenue fell 22.6% over the last 12 months.
  • Loss-making. Operating margin is -151.6%: costs exceed revenue.
  • Burning cash. Free cash flow was -121.3% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 33.6% of revenue, against a median of 9.7% for health care technology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 25.9% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 82% and a beta of 0.3 against the S&P 500.

Latest results: FY2026 Q2

Filed August 11, 2026
Earnings per share
-$0.73 against an average estimate of -$0.76: beat by 3.9%
Revenue
$5m, down 3.6% on a year earlier
Next report
November 12, 2026; average EPS estimate -$0.51

Dariohealth's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.0%
  • 1 week-10.9%
  • 1 month-53.1%
  • This year-73.4%
  • 1 year-78.3%
  • 5 years-99.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$21M
Operating margin
-151.6%
Net margin
-169.9%

Growth

Revenue growth
−22.6%
Change in growth rate
+1.8 pts

Cash

Free cash flow (TTM)
-$25.5M
FCF margin
-121.3%
Stock pay % of revenue
33.6%

Earnings

Last results
July 24, 2023

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Leadership
  3. Leadership
  4. Agreement
  5. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Dariohealth Corp. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Dariohealth Corp. as an operating company, with every model that fits that kind of business. Cost of equity 9.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.99 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$1.1 ~$1.6–$12 Included, half weight
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$1.1 ~$1.1–$12 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Dariohealth Corp. with Health Care Technology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025
Share price$65.00$32.04$15.52$131.20$285.80$259.40$85.60$34.40$15.72$11.38
Market value$4m$4m$2m$15m$85m$215m$101m$49m$39m$45m
+ Net debt (− = net cash)−$1m−$4m−$11m−$20m−$29m−$36m−$22m−$8m$1m$9m
Enterprise value$3m$138117−$9m−$6m$57m$179m$79m$41m$40m$54m
Multiples
Price / sales 1.5x0.7x0.2x2.0x11.2x10.5x3.7x2.4x1.4x2.0x
Price / earnings ——————————
Price / free cash flow ——————————
EV / EBITDA ——————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

8 /100

Weak moat

How hard Dariohealth's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -53.0% of total assets over 10 years.

  • Pricing power 3 / 20

    Gross margin has been a median 29.7%, moving by 16.7 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -280.9%; its worst year was -393.3%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 10 years, at a median -201.5% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 341.4% over five years; stock-based pay has been a median 71.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (13 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, before the open. Analysts expect revenue of $5m and EPS of −$0.51 (range −$0.51 to −$0.51) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.46 +66% $22m −3%
Next −$1.12 +55% $29m +36%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −4.1% on 90 days ago. In the last 30 days, 1 analyst raised Dariohealth Corp.'s forecast and 0 cut it.

Consensus EPS forecast Dariohealth Corp., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.57 Current fiscal year, 60 days ago: −$2.81 Current fiscal year, 30 days ago: −$2.81 Current fiscal year, 7 days ago: −$2.81 Current fiscal year, Now: −$2.46 −$2.46 Next fiscal year, 90 days ago: −$0.66 Next fiscal year, 60 days ago: −$0.68 Next fiscal year, 30 days ago: −$0.68 Next fiscal year, 7 days ago: −$0.68 Next fiscal year, Now: −$1.12 −$1.12

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.57−$0.66
60 days ago −$2.81−$0.68
30 days ago −$2.81−$0.68
7 days ago −$2.81−$0.68
Now −$2.46−$1.12

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.76 −$0.73 +3.9%
Mar 2026 −$0.85 −$0.95 −12.3%
Dec 2025 −$1.59 −$0.77 +51.9%
Sept 2025 −$2.42 −$2.22 +8.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, July 24, 2023

No numeric guidance in Dariohealth Corp.'s latest earnings release (filed July 24, 2023). Some companies give their outlook only on the earnings call.

Analyst recommendations

6 analysts, Oct 2026
Buy583%
Hold117%
Sell00%

Monthly trend

  1. Oct 2026516
  2. Sep 2026415
  3. Aug 2026415
  4. Jul 2026314

Counts of recommendations published by analysts covering Dariohealth Corp., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
0.9%
of tradable shares
Days to cover
4.48
at average volume
Short interest, 1 month
+4%
to October 15, 2026
Held by institutions
9%
of shares
Held by insiders
21.7%
of shares
Employees
160
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
DRIO−9%−67%−60%−54%−28%−73%
Industry peers (median)−14%−60%−16%−8%−27%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
DRIO50%17%42%33%25%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
DRIO−66%−74%−84%−75%−80%−78%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since March 14, 2016: 100% from February 12, 2021 to October 30, 2026. Getting back needed a 20180% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.00 – $14.00
From 52-week high
−78.4%
vs 50-day average
−48.6%
vs 200-day average
−60.6%
Volatility (1 year)
82%
Beta vs S&P 500
0.26

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 4 down
typical move ±14.2%
After a week
1 up, 4 down
typical move ±12.2%
After a month
1 up, 4 down
typical move ±21.5%
Results releasedNext dayS&P 500 next day5 days21 days
July 24, 2023 −18.2% +0.7% −11.8% −33.6%
February 6, 2023 +12.5% +0.7% +2.1% −3.9%
August 15, 2022 −18.2% +0.6% −26.4% −41.9%
January 19, 2022 −10.7% −2.1% −17.4% −19.0%
August 16, 2021 −11.6% −0.4% −3.4% +9.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Dariohealth Corp. in five measures

Fundamentals grade E
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Dariohealth Corp.
$15M $20M $25M $30M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $23.5M Revenue (TTM), FY23 Q4: $20.4M Revenue (TTM), FY24 Q1: $19M Revenue (TTM), FY24 Q2: $19.1M Revenue (TTM), FY24 Q3: $23.1M Revenue (TTM), FY24 Q4: $27M Revenue (TTM), FY25 Q1: $28M Revenue (TTM), FY25 Q2: $27.1M Revenue (TTM), FY25 Q3: $24.7M Revenue (TTM), FY25 Q4: $22.4M Revenue (TTM), FY26 Q1: $21.2M Revenue (TTM), FY26 Q2: $21M $21M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $23.5M
FY23 Q4 $20.4M
FY24 Q1 $19M
FY24 Q2 $19.1M
FY24 Q3 $23.1M
FY24 Q4 $27M
FY25 Q1 $28M
FY25 Q2 $27.1M
FY25 Q3 $24.7M
FY25 Q4 $22.4M
FY26 Q1 $21.2M
FY26 Q2 $21M
Revenue growth, TTM YoY Dariohealth Corp.
-40% -20% 0% 20% 40% 60% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -12.4% Revenue growth, TTM YoY, FY23 Q4: -26.4% Revenue growth, TTM YoY, FY24 Q1: -28.6% Revenue growth, TTM YoY, FY24 Q2: -28.1% Revenue growth, TTM YoY, FY24 Q3: -2.1% Revenue growth, TTM YoY, FY24 Q4: 32.9% Revenue growth, TTM YoY, FY25 Q1: 47.2% Revenue growth, TTM YoY, FY25 Q2: 41.8% Revenue growth, TTM YoY, FY25 Q3: 7.3% Revenue growth, TTM YoY, FY25 Q4: -17.3% Revenue growth, TTM YoY, FY26 Q1: -24.4% Revenue growth, TTM YoY, FY26 Q2: -22.6% -22.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -12.4%
FY23 Q4 -26.4%
FY24 Q1 -28.6%
FY24 Q2 -28.1%
FY24 Q3 -2.1%
FY24 Q4 32.9%
FY25 Q1 47.2%
FY25 Q2 41.8%
FY25 Q3 7.3%
FY25 Q4 -17.3%
FY26 Q1 -24.4%
FY26 Q2 -22.6%
Operating margin (TTM) Dariohealth Corp.
-400% -300% -200% -100% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -216.5% Operating margin (TTM), FY23 Q4: -276.1% Operating margin (TTM), FY24 Q1: -323.7% Operating margin (TTM), FY24 Q2: -333.2% Operating margin (TTM), FY24 Q3: -261.5% Operating margin (TTM), FY24 Q4: -213.6% Operating margin (TTM), FY25 Q1: -175.9% Operating margin (TTM), FY25 Q2: -155.8% Operating margin (TTM), FY25 Q3: -160.8% Operating margin (TTM), FY25 Q4: -163.9% Operating margin (TTM), FY26 Q1: -163.1% Operating margin (TTM), FY26 Q2: -151.6% -151.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -216.5%
FY23 Q4 -276.1%
FY24 Q1 -323.7%
FY24 Q2 -333.2%
FY24 Q3 -261.5%
FY24 Q4 -213.6%
FY25 Q1 -175.9%
FY25 Q2 -155.8%
FY25 Q3 -160.8%
FY25 Q4 -163.9%
FY26 Q1 -163.1%
FY26 Q2 -151.6%
FCF margin (TTM) Dariohealth Corp.
-300% -200% -100% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -133.9% FCF margin (TTM), FY23 Q4: -152.1% FCF margin (TTM), FY24 Q1: -206.4% FCF margin (TTM), FY24 Q2: -213.7% FCF margin (TTM), FY24 Q3: -170.8% FCF margin (TTM), FY24 Q4: -143.1% FCF margin (TTM), FY25 Q1: -115.0% FCF margin (TTM), FY25 Q2: -99.2% FCF margin (TTM), FY25 Q3: -108.9% FCF margin (TTM), FY25 Q4: -116.7% FCF margin (TTM), FY26 Q1: -120.0% FCF margin (TTM), FY26 Q2: -121.3% -121.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -133.9%
FY23 Q4 -152.1%
FY24 Q1 -206.4%
FY24 Q2 -213.7%
FY24 Q3 -170.8%
FY24 Q4 -143.1%
FY25 Q1 -115.0%
FY25 Q2 -99.2%
FY25 Q3 -108.9%
FY25 Q4 -116.7%
FY26 Q1 -120.0%
FY26 Q2 -121.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 0 1 3 5 7 8 8 21 28 20 27 22 21
Gross profit 0 −3 −1 −1 1 2 3 3 4 10 6 13 13 12
EBITDA −13 −11 −7 −11 −14 −17 −18 −30 −76 −56 −56 −56 −36 −32
Operating income −14 −11 −8 −11 −14 −18 −18 −30 −76 −57 −56 −58 −37 −32
Net income −14 −13 −7 −11 −16 −18 −18 −29 −77 −62 −59 −43 −42 −36
Diluted EPS $304.00 $148.00 $307.20 $8.36 $6.56 $156.30 $8.00 $80.20 $4.07 $2.54 $1.93 $12.27 $10.12 —
Growth (year on year)
Revenue — — +>999% +240.6% +84.4% +43.0% +2.2% +0.2% +170.8% +34.8% −26.4% +32.9% −17.3% −22.6%
Diluted EPS — −51.3% — — — — — — — — — — — —
Margins
Gross margin — <−999% −103.9% −29.6% 25.4% 23.9% 34.4% 33.2% 19.3% 34.9% 29.4% 49.1% 56.6% 58.2%
EBITDA margin — <−999% −894.7% −382.2% −275.1% −236.4% −231.8% −392.2% −371.5% −204.1% −273.8% −208.6% −162.6% −150.4%
Operating margin — <−999% −935.4% −396.0% −278.9% −239.2% −234.2% −394.7% −372.9% −205.4% −276.1% −213.6% −163.9% −151.6%
Net margin — <−999% −867.8% −388.4% −304.5% −240.8% −234.6% −388.7% −374.2% −224.9% −292.0% −158.1% −186.6% −169.9%
Free-cash-flow margin — <−999% −776.1% −327.8% −209.2% −156.1% −209.3% −235.7% −247.0% −174.6% −152.1% −143.1% −116.7% −121.3%
Cash flow
Cash from operations −8 −9 −6 −8 −11 −11 −16 −18 −50 −48 −30 −39 −26 −25
Capital spending 1 1 0 1 0 0 0 0 0 0 1 0 0 0
Free cash flow −9 −9 −6 −9 −11 −12 −16 −18 −51 −48 −31 −39 −26 −25
Stock-based pay 2 1 1 1 4 4 2 11 25 17 20 0 9 7
Free cash flow after stock pay −11 −10 −8 −10 −15 −15 −18 −29 −76 −65 −51 −39 −35 −33
Balance sheet
Cash 2 1 3 1 4 11 20 29 36 49 37 28 22 7
Total debt 0 0 0 0 0 0 0 0 0 27 29 29 31 31
Net debt (negative = net cash) −2 −1 −3 −1 −4 −11 −20 −29 −36 −22 −8 1 9 24
Diluted shares — — — — — — — — — 1m 1m 2m 4m —
Returned to shareholders
Buybacks — — — — — — — — — 0 — — — —
Total returned — — — — — — — — — 0 — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 6 checks passed · June 30, 2026
What it owns · $97m
Short-term assets $22mLonger-term assets $74m
What it owes, and who funded it · $65m
Short-term liabilities $10mShareholders' equity $55m
  • Short-term assets cover short-term liabilities $22m of assets due within a year against $10m of liabilities due within a year.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt $7m of cash against $31m of debt.
  • Debt below 40% of shareholders' equity Debt is 56% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 56% over five years.
  • A year's operating cash flow covers at least 20% of debt −$25m of operating cash flow against $31m of debt.
  • Operating profit covers interest at least five times over Operating income of −$32m against $5m of interest.

From Dariohealth Corp.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
49.8%
of revenue

Competitors: side by side with peers

Closest by revenue in health care technology
Last 12 months unless stated DRIO HCTI MNDR SOPH OPRX CCLD Median
Revenue, last 12 months $21m $26m $8m $77m $99m $129m $292m
Revenue growth, last 12 months −22.6% 116.4% 1.2% 18.6% −5.8% 15.1% 8.8%
Revenue growth, 3-year average −7.6% −14.9% — — 17.0% 0.8% 0.8%
Revenue growth, latest quarter −3.6% 158.4% — — −29.8% 16.4% 7.4%
Gross margin 58.2% 21.5% 21.2% 67.4% 73.2% — 58.6%
Operating margin −151.6% −57.4% — −91.8% 11.1% 7.1% −12.5%
Operating margin, 3-year average −213.6% −40.6% — — −6.8% −7.0% −18.8%
Net margin −169.9% −66.3% −41.2% −102.2% 4.7% 6.2% −12.5%
Cash from operations / revenue −120.7% −62.4% −19.7% −46.5% 18.7% 20.8% 9.7%
Free-cash-flow margin −121.3% −62.4% −19.7% −47.2% 18.6% 17.7% 9.2%
Free-cash-flow margin, 3-year average −144.7% −44.7% — — 8.7% 16.7% 8.2%
Stock pay / revenue 33.6% 3.2% 19.9% 21.0% 8.1% 0.3% 9.5%
Change in share count 25.9% — 265.5% 2.2% 2.5% 73.1% 2.9%

Median of all 23 companies we cover in health care technology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

23 health care technology companies
Measure Company Peer median Rank
Revenue growth Growth -22.6% 8.8% 23 of 23
Change in growth rate Growth +1.8pp -0.3pp 9 of 23
Gross margin Profitability 58.2% 58.2% 7 of 14
Operating margin Profitability -151.6% -6.6% 20 of 22
Net margin Profitability -169.9% -12.5% 21 of 23
Free-cash-flow margin Cash generation -121.3% 10.6% 20 of 22
Stock pay as % of revenue Cash generation 33.6% 9.7% 20 of 22
Long-term debt as % of assets Balance sheet 32.2% 20.1% 14 of 15

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Services $14.9M 66.8% ▼ 26.1%
Hardware and Consumable Products $7.4M 33.2% ▲ 8.6%

From Dariohealth Corp.'s 10-K filed March 19, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Insider trading activity

Full insider history and chart
Insider purchases History → $100,000 1 trade by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $100,000 net buying
Insider Date Trade Shares Price Value
Matheis Dennis Director July 23, 2026 Buy 14,430 $6.93 $100,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • July 24, 2023
  • February 6, 2023
  • August 15, 2022
  • January 19, 2022
  • August 16, 2021

Recent SEC filings

Data status

When each part of this page on Dariohealth Corp. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Dariohealth Corp. in brief

What does Dariohealth Corp. do?
Dariohealth Corp. is a US-listed company in the health care technology industry. Its financial year ends in December.
What is Dariohealth Corp.'s stock ticker?
Dariohealth Corp. trades under the ticker DRIO on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Dariohealth Corp.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Dariohealth Corp. reported revenue of $21M, 22.6% lower than a year earlier, according to its SEC filings.
What is Dariohealth Corp.'s free cash flow?
Dariohealth Corp.'s free-cash-flow margin is -121.3% of revenue over the trailing twelve months, ranking 20 of the 22 health care technology companies we cover.
What is Dariohealth Corp.'s market cap?
On December 31, 2025, Dariohealth Corp.'s market capitalisation was about $45.3M and net debt of $8.9M. Market figures come from third-party market data and may be delayed.
How much debt does Dariohealth Corp. have?
Dariohealth Corp.'s debt-to-equity ratio is 56.4%, from its latest balance sheet (0.0% five years earlier). The financial health section below sets out its other solvency checks.
Who are Dariohealth Corp.'s competitors?
In our Health Care Technology peer group, the companies closest to Dariohealth Corp. are Healthcare Triangle, Inc., Mobile-health Network Solutions, Sophia Genetics SA, Optimizerx Corp and Carecloud, Inc. The side-by-side comparison below sets their revenue, margins and growth against Dariohealth Corp.'s.
Are insiders buying or selling Dariohealth Corp. stock?
Over the last 12 months, Dariohealth Corp.'s directors and officers reported 1 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Dariohealth Corp.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Dariohealth Corp. announces its own schedule.